2024
The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review
Huelsboemer L, Moscarelli J, Dony A, Boroumand S, Kochen A, Knoedler L, Yu C, Hauc S, Stögner V, Formica R, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review. Frontiers In Transplantation 2024, 3: 1442006. PMID: 39291278, PMCID: PMC11405992, DOI: 10.3389/frtra.2024.1442006.Peer-Reviewed Original ResearchDonor-specific antibodiesSerum donor-specific antibodiesAntibody-mediated rejectionHigher rejection gradesVascularized composite allotransplantationC4d depositionRejection gradeCellular rejectionRejection episodesSpecific antibodiesDonor-specific antibody statusManagement of antibody-mediated rejectionFace transplantationAcute cellular rejectionAcute rejection episodesAssociated with high gradeTime of biopsyAntibody mediated rejectionFisher's exact testMann-Whitney U testSystematic review of electronic databasesMechanisms of rejectionSystematic reviewReview of electronic databasesC4d staining
2019
Novel immunological and clinical insights in vascularized composite allotransplantation
Kollar B, Pomahac B, Riella L. Novel immunological and clinical insights in vascularized composite allotransplantation. Current Opinion In Organ Transplantation 2019, 24: 42-48. PMID: 30531538, DOI: 10.1097/mot.0000000000000592.Peer-Reviewed Original ResearchConceptsAcute rejectionT cellsComposite allotransplantationField of VCANovel immunosuppressive approachAntibody-mediated rejectionCurrent histological classificationNovel noninvasive biomarkersQuality of lifeType of rejectionIntensity of treatmentFace transplant recipientsChronic rejectionImmunosuppressive regimensVCA patientsVCA recipientsAllograft injuryCostimulation blockadeImmunosuppressive approachesImmunosuppressive therapyTransplant recipientsImmune monitoringUpper extremityHistological classificationVCA outcomes
2015
Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration
Kueckelhaus M, Fischer S, Seyda M, Bueno E, Aycart M, Alhefzi M, ElKhal A, Pomahac B, Tullius S. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transplant International 2015, 29: 655-662. PMID: 26265179, PMCID: PMC4785085, DOI: 10.1111/tri.12652.Peer-Reviewed Original ResearchConceptsAcute rejectionImproved long-term graft outcomesLong-term graft outcomeChronic allograft deteriorationCytomegalovirus infection statusGraft preservation techniquesUpper extremity transplantationUpper extremity transplantsAntibody-mediated rejectionGood midterm resultsSpecific treatment strategiesAllograft deteriorationChronic rejectionClinical VCAVCA graftsGraft outcomeImmunosuppressive strategiesLocal immunosuppressionMidterm resultsExtremity transplantationCell-based therapiesHLA matchingTolerance inductionTreatment strategiesUS Centers
2014
The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant
Chandraker A, Arscott R, Murphy G, Lian C, Bueno E, Marty F, Rennke H, Milford E, Tullius S, Pomahac B. The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant. American Journal Of Transplantation 2014, 14: 1446-1452. PMID: 24797454, DOI: 10.1111/ajt.12715.Peer-Reviewed Original ResearchConceptsAntibody-mediated rejectionPostoperative day 5Management of AMRDonor-specific antibody titersSubsequent antibody-mediated rejectionGrade III rejectionStandard induction regimenAnti-HLA antibodiesExtensive chemical burnsComposite tissue allotransplantationFull face transplantationMechanism of actionPreoperative crossmatchPresensitized recipientsSensitized recipientsDSA levelsInduction regimenC4d depositsPositive donorsBanff classificationAntibody titersCombination therapyPoor functionHistological signsClinical signs